This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
AquaBounty Technologies, Inc. (AQB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 20% and 23.18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AquaBounty Technologies, Inc. (AQB) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 11.11% and 12.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 12.50% and 31.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) Stock Jumps 8.6%: Will It Continue to Soar?
by Zacks Equity Research
Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
AquaBounty Technologies, Inc. (AQB) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 0% and 56.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
AquaBounty Technologies, Inc. (AQB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of -42.86% and -40.37%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
AquaBounty Technologies, Inc. (AQB) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AquaBounty Technologies, Inc. (AQB) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of -40.00% and -57.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Top ETF of December & Its Best Stocks
by Sweta Killa
We have highlighted the best ETF of December and its best performing stocks.
AquaBounty (AQB) Surges: Stock Moves 6.3% Higher
by Zacks Equity Research
AquaBounty (AQB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
AquaBounty Technologies, Inc. (AQB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AquaBounty (AQB) Catches Eye: Stock Jumps 8.9%
by Zacks Equity Research
AquaBounty (AQB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 15.38% and -30.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Will AquaBounty Technologies, Inc. (AQB) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus (FOLD) Provides Updates on AT-GAA for Pompe Disease
by Zacks Equity Research
Amicus (FOLD) announces updates on its investigational therapy, AT-GAA, for Pompe disease.
AquaBounty Technologies, Inc. (AQB) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes AquaBounty Technologies, Inc. (AQB) a New Strong Buy Stock
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AquaBounty Technologies, Inc. (AQB) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 22.22% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will AquaBounty Technologies, Inc. (AQB) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will AquaBounty Technologies, Inc. (AQB) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues
by Zacks Equity Research
Intrexon (XON) reports in line loss in the first quarter of 2019. Also, sales miss estimates.
AquaBounty Technologies, Inc. (AQB) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of -5.00% and -92.14%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Humana (HUM) Stock in Q2 Earnings?
by Zacks Equity Research
Humana's (HUM) second quarter is likely to gain traction from solid individual Medicare Advantage membership growth.